Pot stocks, by and large, have had an awful week. Top players like Canopy Growth (NYSE: CGC), Cronos Group (NASDAQ: CRON), and Tilray (NASDAQ: TLRY) have all seen their shares take a step back this week.

Oddly enough, though, these industrywide declines have occurred against the backdrop of Altria Group's (NYSE: MO) massive equity investment in Cronos last week, as well as the passage of the 2018 Farm Bill this week that is intended to legalize hemp in the United States.

Amidst this sea of red, however, there has been one company producing stellar gains for its shareholders over the last few trading sessions. Namely Medical Marijuana (NASDAQOTH: MJNA), which -- despite its name -- does not actually operate in either the medical or recreational side of the cannabis industry, but rather within the confines of the less controversial hemp oil space.

MJNA data by YCharts

Why is Medical Marijuana's stock breaking out this week? Let's dive in to find out.

A change in fundamentals

Unlike Canopy Growth, Cronos Group, or Tilray, which have all benefited immensely from the so-called "green rush" this year, Medical Marijuana's stock has actually lost a significant chunk of its value in 2018. The long-standing issue weighing on the company's share price has been the legal status of products containing cannabidiol (CBD), such as hemp oil.

Despite the company's argument that its products are derived from parts of the cannabis plant excluded from the Controlled Substances Act, hemp itself has been on shaky legal ground for years. That fact has created a black cloud around Medical Marijuana's core business prospects.

Image Source: Getty Images.

Fortunately, the 2018 Farm Bill should remove this particular overhang for CBD-oil producers like Medical Marijuana. And investors are obviously thrilled with this groundbreaking development, based on the sharp reversal in the company's share price this week.

However, Medical Marijuana's shares are also getting a boost from the company's improving fundamentals. Over the first nine months of the year, for instance, the company's revenues topped $42.1 million, according to its third-quarter earnings release.

While that may not sound like a whole lot, it does represent a 146% increase over the same period last year, implying that Medical Marijuana's business is starting to heat up. And with the company's products moving out of the shadows and into the mainstream, this favorable growth trend should continue to gain momentum going forward.